Emerging clinical concerns in the ageing haemophilia patient

Haemophilia

Volumn 15, Issue 6, 2009, Pages 1197-1209

  Konkle, B A ^a   Kessler, C ^b   Aledort, L ^c   Andersen, J ^d   Fogarty, P ^e   Kouides, P ^f   Quon, D ^g   Ragni, M ^h   Zakarija, A ⁱ   Ewenstein, B ^j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Mary M Gooley Hemophilia Center   (United States)

^g JOINT REPLACEMENT INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j BAXTER HEALTHCARE CORPORATION   (United States)

more..

Author keywords

Ageing; Comorbidities; Haemophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ERYTHROPOIETIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA; RIBAVIRIN; VASCULOTROPIN INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; AGING; ARTHRALGIA; ARTHROPATHY; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE ASSOCIATION; DRUG ELUTING STENT; DRUG INFUSION; HEALTH HAZARD; HEART INFARCTION; HEMODIALYSIS; HEMOPHILIA; HEPATITIS C; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; JOINT SURGERY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NEPHROTOXICITY; PERCUTANEOUS CORONARY INTERVENTION; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOSIS;

AGED; BLOOD COAGULATION FACTORS; CARDIOVASCULAR DISEASES; COMORBIDITY; FACTOR VIII; HEMOPHILIA A; HUMANS; JOINT DISEASES; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 70449553036     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02066.x     Document Type: Article

References (136)

1. Darby SC, Kan SW, Spooner RJ. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007, 110:815-25.
2. Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001, 66:229-40.
3. Lusher J. Management of hematologic disorders. 2004, http://www.medscape.com/viewarticle/496545, Presentation at the American Society of Hematology 46th Annual Meeting, San Diego, CA, December 4-7, Available at: , 2004
4. Soucie JM, Nuss R, Evatt B. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000, 96:437-42.
5. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004, 2:1047-54.
6. National Center for Health Statistics. 2004, http://www.cdc.gov/nchs/fastats/deaths.htm, Deaths: leading causes for, Available at:
7. Conlan MG, Folsom AR, Finch A. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993, 70:380-5.
8. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, Biesma DH, Schutgens RE. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009, 7:247-54.
9. Rosendaal FR, Varekamp I, Smit C. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989, 71:71-6.
10. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995, 123:823-7.
11. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003, 362:351-4.
12. Girolami A, Ruzzon E, Fabris F. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006, 116:120-5.
13. Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol 2005, 79:36-42.
14. Carroll K, Majeed A, Firth C, Gray J. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003, 25:29-35.
15. Foley C, Nichols LA, Ragni MV. Atherosclerosis and predictors of cardiovascular mortality in hemophilia. Blood 2008, 112. abstract 1216
16. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629-36.
17. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-52.
18. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-7.
19. Park YW, Zhu S, Palaniappan L. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163:427-36.
20. Ogden CL, Carroll MD, Curtin LR. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-55.
21. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006, 12:241-7.
22. Friis-Moller N, Reiss P, Sabin CA. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-35.
23. van Leth F, Phanuphak P, Stroes E. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.
24. Recommended schedule for screening tests. http://www.americanheart.org/presenter.jhtml?identifier=3046593, Available at:
25. Gibbons RJ, Balady GJ, Bricker JT. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002, 40:1531-40.
26. Elhendy A, van Domburg RT, Roelandt JR. Safety and feasibility of dobutamine-atropine stress testing in hypertensive patients. Hypertension 1997, 29:1232-9.
27. Detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panel III). http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm, Final report. Available at: . (last accessed on 24 September 2008)
28. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006, 119:624-38.
29. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4:902-7. quiz 806
30. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleveland Clin J Med 2004, 71:58-62.
31. Wiviott SD, Cannon CP, Morrow DA. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005, 46:1411-6.
32. Street A, Hill K, Sussex B, Warner M, Scully MF. Haemophilia and ageing. Haemophilia 2006, 12:8-12.
33. Werner GS, Schwarz G, Prochnau D. Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc Interv 2006, 67:1-9.
34. Helft G, Gilard M, Le Feuvre C, Zaman AG. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med 2006, 3:673-80.
35. Seung KB, Park DW, Kim YH. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008, 358:1781-92.
36. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
37. Darby SC, Ewart DW, Giangrande PL. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997, 350:1425-31.
38. Makris M, Preston FE, Rosendaal FR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996, 94:746-52.
39. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001, 183:1112-5.
40. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000, 47:845-51.
41. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999, 31:88-91.
42. Telfer P, Sabin C, Devereux H. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994, 87:555-61.
43. Thabut D, Le Calvez S, Thibault V. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?. Am J Gastroenterol 2006, 101:1260-7.
44. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009, 15:552-8.
45. Goedert JJ, Eyster ME, Lederman MM. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002, 100:1584-9.
46. Daar ES, Lynn H, Donfield S. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001, 26:466-72.
47. Graham CS, Baden LR, Yu E. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-69.
48. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-60.
49. Qurishi N, Kreuzberg C, Luchters G. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-13.
50. Ragni MV, Soadwa K, Nalesnik MA, Dang Q. Predictors of liver fibrosis in hepatitis C (HCV) infected hemophilic men. Hepatology 2008, 48:1935. (abstract)
51. Sauleda S, Martorell M, Esteban JI. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. Haemophilia 2006, 12:228-36.
52. Yano M, Kumada H, Kage M. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996, 23:1334-40.
53. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001, 344:495-500.
54. DiMichele DM, Mirani G, Wilfredo Canchis P, Trost DW, Talal AH. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 2003, 9:613-8.
55. Aledort LM, Levine PH, Hilgartner M. A study of liver biopsies and liver disease among hemophiliacs. Blood 1985, 66:367-72.
56. Imbert-Bismut F, Ratziu V, Pieroni L. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-75.
57. Forns X, Ampurdanes S, Llovet JM. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-92.
58. Maor Y, Bashari D, Kenet G. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?. Haemophilia 2006, 12:372-9.
59. Maor Y, Cales P, Bashari D. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007, 13:722-9.
60. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36:S152-S60.
61. Theodore D, Fried MW, Kleiner DE. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 2004, 10:413-21.
62. MASAC recommendations on liver biospy in individuals with hemophilia. 2000, http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&cont entid=311, Recommendation 98, June, Available at:
63. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med 2006, 355:173-81.
64. EASL international consensus conference on hepatitis C. Consensus statement. J Hepatol 1999, 30:956-61.
65. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003, 59:1-11.
66. Mancuso ME, Rumi MG, Santagostino E. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006, 91:1367-71.
67. Franchini M, Mengoli C, Veneri D. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008, 61:1191-200.
68. Meijer K, Smid WM, van der Meer J. Treatment of chronic hepatitis C in haemophilia patients. Haemophilia 2000, 6:605-13.
69. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 2004, 140:370-81.
70. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998, 42:744-9.
71. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005, 11:1425-30.
72. Ragni MV, Belle SH, Jaffe RA. Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia. Blood 1993, 81:1889-97.
73. Mauser Bunschoten E, Roosendaal G, Schutgens R, Fischer K. Comorbidity in the aging hemophilia patient. Haemophilia 2008, 14:128. abstract 122 PO127
74. Rabkin CS, Hilgartner MW, Hedberg KW. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA 1992, 267:1090-4.
75. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000, 92:1823-30.
76. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-91.
77. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-50.
78. Tradati F, Colombo M, Mannucci PM. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998, 91:1173-7.
79. Guidelines for the early detection of cancer. http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_ Guidelines_36.asp?sitearea=PED, Available at:
80. Preventive Services Task Force (USPSTF) recommendations. http://www.ahrq.gov/clinic/uspstfix.htm, Available at:
81. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-63.
82. Colombo M, de Franchis R, Del Ninno E. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-80.
83. Fattovich G, Giustina G, Schalm SW. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995, 21:77-82.
84. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19:61-6.
85. Pateron D, Ganne N, Trinchet JC. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20:65-71.
86. Santagostino E, Colombo M, Rivi M. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003, 102:78-82.
87. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-36.
88. Graziadei IW, Sandmueller H, Waldenberger P. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003, 9:557-63.
89. Elting LS, Rubenstein EB, Martin CG. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001, 19:1137-46.
90. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003, 21:3542. author reply 3543
91. Lambert C, Deneys V, Pothen D, Hermans C. Safety of bevacizumab in mild haemophilia B. Thromb Haemost 2008, 99:963-64.
92. Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. Haemophilia 2003, 9:703-10.
93. Froom P, Ribak J, Benbassat J. Significance of microhaematuria in young adults. Br Med J (Clin Res Ed) 1984, 288:20-2.
94. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001, 33:115-9.
95. Rao TK. Human immunodeficiency virus infection and renal failure. Infect Dis Clin North Am 2001, 15:833-50.
96. Executive summary. United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis 1999, 34:S9-S19.
97. Rosendaal FR, Briet E, Stibbe J. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990, 75:525-30.
98. Ewenstein BM, Takemoto C, Warrier I. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997, 89:1115-6.
99. Mannucci PM. Hemostatic drugs. N Engl J Med 1998, 339:245-53.
100. Pitts TO, Spero JA, Bontempo FA, Greenberg A. Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. Am J Kidney Dis 1986, 8:441-4.
101. Odabas AR, Cetinkaya R, Selcuk Y, Kaya H, Coskun U. Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A. Nephrol Dial Transplant 2001, 16:189-90.
102. Roy-Chaudhury P, Propper DJ, Catto GRD. Renal replacement therapy for hemophiliacs. J Nephrol 1993, 6:93-4.
103. Fujii T, Takata N, Saito S, Naito T, Kimura A. Management of haemostasis during haemodialysis in a patient with haemophilia B. Haemophilia 2008, 14:1135-7.
104. Bajo MA, del Peso G, Jimenez V. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders. Adv Perit Dial 2000, 16:170-3.
105. Boggio LN, Harris SA, Fryer J, Zakarija A. The use of Advate in liver and kidney transplantation in a patient with hemophilia A, hepatitis C, and HIV. J Thromb Haemost 2007, 5. abstract P-S-140
106. Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia 1999, 5:266-9.
107. Wilde JT, Lee CA, Collins P. Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 1999, 107:556-9.
108. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977, 59:287-305.
109. Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol 2006, 43:S18-S22.
110. Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost 2003, 29:37-42.
111. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev 2004, 18:101-13.
112. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
113. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994, 236:391-9.
114. Fischer K, van der Bom JG, Molho P. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002, 8:745-52.
115. Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ. Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. Haemophilia 2007, 13:279-86.
116. Srivastava A, Giangrande P, Poon MC. WFH Guidelines for the management of hemophilia. http://www.wfh.org/index.asp?lang=EN, Available at: . (last accessed on 28 March 2008)
117. York J, Rodriguez-Merchan EC, Lee CA. Haemophilia patients with inhibitors: a rheumatologist's point of view. Inhibitors in Patients with Haemophilia 2002, 146-8. In, eds, Oxford, UK, Blackwell Science, Ltd
118. Medeiros D, Laufenberg JA, Miller KL, Buchanan GR. Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors. Haemophilia 2007, 13:85-9.
119. Blanchette VS, Shapiro AD, Liesner RJ. Plasma and albumin free recombinant factor VIII (rAHF-PFM): pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008, 6:1319-26.
120. van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003, 9:27-31.
121. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med 1997, 241:395-400.
122. Astermark J. When to start and when to stop primary prophylaxis in patients with severe haemophilia. Haemophilia 2003, 9:32-6.
123. Geraghty S, Dunkley T, Harrington C. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006, 12:75-81.
124. Khair K, Lawrence K, Butler R, O'Shea E, Christie BA. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008, 119:115-23.
125. Pipe SW, Valentino LA. Optimizing outcomes for patients with severe hemophilia A. Haemophilia 2007, 13:1-16.
126. Trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult subjects compared to that of episodic treatment (SPINART). http://www.clinicaltrials.gov/ct2/show/NCT00623480?term=hemophilia+and+p rophylaxis+and+adults&rank=2, ClinicalTrials.gov Available at. . (last accessed on 30 July 2008)
127. Siegel HJ, Luck JV, Siegel ME, Quinones C. Phosphate-32 colloid radiosynovectomy in hemophilia: outcome of 125 procedures. Clin Orthop Relat Res 2001, 392:409-17.
128. Dunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop 2004, 24:414-26.
129. Journeycake JM, Miller KL, Anderson AM, Buchanan GR, Finnegan M. Arthroscopic synovectomy in children and adolescents with hemophilia. J Pediatr Hematol Oncol 2003, 25:726-31.
130. Luck JV, Silva M, Rodriguez-Merchan EC. Hemophilic arthropathy. J Am Acad Orthop Surg 2004, 12:234-45.
131. Rivard GE, Girard M, Belanger R. Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg Am 1994, 76:482-88.
132. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005, 3:1541-42.
133. Goddard NJ, Lee CA, Berntorp EE, Hoots WK. Joint replacement. Textbook of Hemophilia 2005, 164-8. In, eds, Malden, MA, Blackwell Publishing Ltd
134. Goddard NJ, Rodriguez-Merchan EC, Wiedel JD. Total knee replacement in haemophilia. Haemophilia 2002, 8:382-6.
135. Radin S, Campbell JT, Ducheyne P, Cuckler JM. Calcium phosphate ceramic coatings as carriers of vancomycin. Biomaterials 1997, 18:777-82.
136. Glimet T, Masse JP, Kuntz D. Obesity and arthritis of the knee. Rev Rhum Mal Osteoartic 1990, 57:207-9.